ARYA Sciences Acquisition Corp IV

ARYA Sciences Acquisition Corp. IV operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on August 24, 2020 by Joseph Eric Edelman, Adam Stone, Michael R. Altman, and Poukalov Konstantin and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adagio Medical Holdings, Inc. is a medical device company, which engages in the development and placing on the EU market of innovative ablation technologies for the treatment of cardiac arrhythmias. It treats atrial fibrillation, atrial flutter, and ventricular tachycardia. The company was founded on August 24, 2020 and is headquartered in New York, NY.

LAGUNA HILLS, Calif. & NEW YORK--(BUSINESS WIRE)--Adagio Medical, Inc. (“Adagio Medical”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD; or “ARYA IV”), a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, LLC (“Perceptive Advisors”). Upon closing the transaction, the shares of common stock of the combine.

Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias

Combined Company expects to receive approximately $42 million from equity and convertible note investors at closing. LAGUNA HILLS, Calif.

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately.

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus' Gene Therapy Business Due to Market Conditions

News for ARYA Sciences Acquisition Corp IV Stock (ARYD)